Zacks Investment Research upgraded shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. They currently have $4.75 price target on the stock.
According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “
OSMT has been the subject of a number of other research reports. Royal Bank of Canada reaffirmed a buy rating and issued a $10.00 price target on shares of Osmotica Pharmaceuticals in a research note on Wednesday, March 25th. Wells Fargo & Co downgraded Osmotica Pharmaceuticals from an overweight rating to an equal weight rating and set a $4.00 price target for the company. in a research note on Monday, March 23rd. ValuEngine downgraded Osmotica Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, March 30th. SunTrust Banks assumed coverage on Osmotica Pharmaceuticals in a research note on Wednesday, March 18th. They set a buy rating and a $8.00 target price for the company. Finally, BidaskClub downgraded Osmotica Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, February 4th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $8.25.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.07. The business had revenue of $48.65 million during the quarter, compared to the consensus estimate of $43.76 million. Osmotica Pharmaceuticals had a negative return on equity of 6.22% and a negative net margin of 115.34%. As a group, research analysts anticipate that Osmotica Pharmaceuticals will post -0.67 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its stake in shares of Osmotica Pharmaceuticals by 47.2% in the first quarter. Meeder Asset Management Inc. now owns 11,216 shares of the company’s stock valued at $35,000 after buying an additional 3,597 shares during the period. State of Tennessee Treasury Department acquired a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at approximately $26,000. Barclays PLC increased its stake in shares of Osmotica Pharmaceuticals by 103.0% in the fourth quarter. Barclays PLC now owns 8,226 shares of the company’s stock valued at $57,000 after buying an additional 4,174 shares during the period. Citigroup Inc. increased its stake in shares of Osmotica Pharmaceuticals by 330.6% in the fourth quarter. Citigroup Inc. now owns 5,598 shares of the company’s stock valued at $39,000 after buying an additional 4,298 shares during the period. Finally, Martingale Asset Management L P increased its stake in shares of Osmotica Pharmaceuticals by 13.9% in the first quarter. Martingale Asset Management L P now owns 54,740 shares of the company’s stock valued at $175,000 after buying an additional 6,700 shares during the period. 7.68% of the stock is owned by institutional investors.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.